Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Non-Hodgkin Lymphoma Similar Videos
-
Appropriate indications and methods of administration of CNS prophylaxis in aggressive NHL_Victor Orellana-Noia, MD; #DDHO2021
1:36
-
Ann LaCasce, MD; Dana-Farber Cancer Institute; 5Live #ASH21
5:21
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
John P. Leonard, MD; Weill Cornell Medicine #BtC_ASCO21
16:48
Dr. John Leonard discusses Recently Presented Data of Clinical Trials in Patients with NHL.